NDT Advance Access published online on January 5, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfk048
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Nephrology, Odense University Hospital, Odense, Denmark
* To whom correspondence should be addressed. Background. The erythropoiesis-stimulating protein darbepoetin alfa (Aranesp®) can be given intravenously (IV) or subcutaneously (SC). Despite a SC bioavailability of only 37%, darbepoetin alfa IV or SC dose requirements were comparable in previous studies designed to evaluate other aspects of anaemia treatment. The present study was designed to compare IV vs SC dose requirements. Methods. A single-centre open-label, prospective and randomized crossover study was undertaken in 71 stable haemodialysis patients. After a run-in period randomized to a 20 week study treatment with either SC or IV darbepoetin alfa, the patients were crossed over to the other treatment modality for another 20 week study period. The unit dose of weekly darbepoetin alfa was adjusted to maintain each patient's haemoglobin within a target range of -0.8 to +0.8 mmol/l of the individual baseline haemoglobin and between 6.8 and 8.5 mmol/l throughout the study period. The primary endpoint was the mean dose of darbepoetin alfa necessary to maintain the haemoglobin level in the defined range. Results. Data from 58 patients were available for analysis. Haemoglobin concentrations were maintained effectively in subjects, regardless of whether they received darbepoetin alfa IV or SC. The overall mean difference in haemoglobin levels during SC or IV was 0.052 mmol/l (95% confidence interval: -0.132 to 0.236 mmol/l). The difference had no statistical or clinical significance. The population mean darbepoetin alfa dose during IV treatment was 32.1 µg/week, compared with a mean value for SC treatment of 34.1 µg/week. A paired two-tailed ratio t-test showed that P = 0.036, indicating a 95% probability of a mean dose reduction between 1.2% and 28% by IV treatment instead of SC. Conclusions. Renal anaemia of stable haemodialysis patients can be treated with darbepoetin alfa more effectively by the IV as compared with the SC route.
Received July 31, 2005
Accepted December 13, 2005
Original Article
Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa
Michael Aarup 1,
Julie Bryndum 1,
Hans Dieperink 1 *,
and
Preben Joffe 1
Hans Dieperink, E-mail: hans.dieperink{at}ouh.fyns-amt.dk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Bonafont, A. Bock, D. Carter, R. Brunkhorst, F. Carrera, M. Iskedjian, B. Molemans, B. Dehmel, and S. Robbins A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis NDT Plus, October 1, 2009; 2(5): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bommer, G. Asmus, M. Wenning, and G. Bommer A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4002 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|